Incyte Q3 2023 revenues up 12% to $919M; Jakafi guidance tightened to $2.59-2.62B

INCYTE CORP

2023-Q3 EPS reported $1.76 revenue$2,682,308,000

Total GAAP revenues of $919M (+12% YoY); GAAP net income $171M ($0.76 diluted EPS).
Jakafi net product revs $636M (+3% YoY); Opzelura $92M (+141% YoY) on AD/vitiligo demand.
Non-GAAP diluted EPS $1.10 vs $0.60 in Q3 2022; operating income up 63% to $273M.
FY 2023 Jakafi guidance tightened to $2.59-2.62B from $2.58-2.63B; other guidance unchanged.
Phase 2 povorcitinib in prurigo nodularis met primary endpoint; Phase 3 planned for 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

INCYTE CORP reported third fiscal quarter ended September 30, 2023 results: revenue $919 million. Guidance reaffirmed.

Period: third fiscal quarter ended September 30, 2023
Revenue: $919 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs – Total revenues of $919 million in the third quarter (Q3'23)

View on SEC.gov

Browse all earnings releases →

INCYTE CORP filing history →

Source: SEC EDGAR

accession 0000879169-23-000038

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.